Published in Neurology on December 01, 1998
Evidence for complex system integration and dynamic neural regulation of skeletal muscle recruitment during exercise in humans. Br J Sports Med (2004) 1.69
Frequency specific activity in subthalamic nucleus correlates with hand bradykinesia in Parkinson's disease. Exp Neurol (2012) 1.55
Clinical characteristics of elderly patients with a cautious gait of unknown origin. J Neurol (2005) 1.13
Community walking in people with Parkinson's disease. Parkinsons Dis (2011) 0.96
Acute basal ganglia infarcts in poststroke fatigue: an MRI study. J Neurol (2009) 0.93
Rate-dependent impairments in repetitive finger movements in patients with Parkinson's disease are not due to peripheral fatigue. Neurosci Lett (2010) 0.83
Impact of endurance exercise on levodopa-associated cortisol release and force increase in patients with Parkinson's disease. J Neural Transm (Vienna) (2008) 0.78
Effect of high-frequency repetitive transcranial magnetic stimulation on major depressive disorder in patients with Parkinson's disease. J Neurol (2016) 0.77
What is orofacial fatigue and how does it affect function for swallowing and speech? Semin Speech Lang (2006) 0.77
Parkinson's disease and fatigue. J Neurol (2006) 0.76
Enhanced fatigue during motor performance in patients with PD. Neurology (1999) 0.75
Sequence Effect in Parkinson's Disease Is Related to Motor Energetic Cost. Front Neurol (2016) 0.75
Rethinking energy in parkinsonian motor symptoms: a potential role for neural metabolic deficits. Front Syst Neurosci (2015) 0.75
Chemical characterization of element 112. Nature (2007) 2.12
Relapsing myelitis. Neurology (1992) 2.12
Camptocormia (bent spine) in patients with Parkinson's disease--characterization and possible pathogenesis of an unusual phenomenon. Mov Disord (1999) 1.94
Mesenchymal stem cells induced to secrete neurotrophic factors attenuate quinolinic acid toxicity: a potential therapy for Huntington's disease. Exp Neurol (2012) 1.91
Quantitative measurement of pain sensation in patients with Parkinson disease. Neurology (2004) 1.84
Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology (2001) 1.83
Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Proc Natl Acad Sci U S A (2001) 1.62
Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis. Arch Neurol (1992) 1.61
Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology (1995) 1.57
The LRRK2 G2019S mutation is associated with Parkinson disease and concomitant non-skin cancers. Neurology (2012) 1.56
Evaluating dosage compensation on the chicken Z chromosome: should effective dosage compensation eliminate sexual bias? Heredity (Edinb) (2009) 1.55
Antibodies from ALS patients inhibit dopamine release mediated by L-type calcium channels. Neurology (1998) 1.41
Riluzole for levodopa-induced dyskinesias in advanced Parkinson's disease. Lancet (1999) 1.40
Transient regional and migratory osteoporosis. A possible neural mechanism. Isr J Med Sci (1988) 1.40
Reduction in regional cerebral blood flow during normal aging in man. Stroke (1980) 1.34
Precursor control of neurotransmitter synthesis. Pharmacol Rev (1980) 1.34
Tardive dyskinesia associated with metoclopramide. Br Med J (1978) 1.33
Semaphorins as mediators of neuronal apoptosis. J Neurochem (1999) 1.31
Reactive hyperglycaemia in patients with acute stroke. J Neurol Sci (1976) 1.30
Partial lesions of the dopaminergic nigrostriatal system in rat brain: biochemical characterization. Brain Res (1980) 1.27
Increased plasma endothelin-1 in acute ischemic stroke. Stroke (1992) 1.26
Parkinson Psychosis Rating Scale: a practical instrument for grading psychosis in Parkinson's disease. Clin Neuropharmacol (1998) 1.20
Acute "upside down" reversal of vision in transient vertebrobasilar ischemia. Neurology (1987) 1.20
Effect of chronic atrial fibrillation on regional cerebral blood flow. Stroke (1980) 1.16
IL-1 beta, IL-2, IL-6 and TNF-alpha production by peripheral blood mononuclear cells from patients with Parkinson's disease. Biomed Pharmacother (1999) 1.15
Neurotransmitters and the fifth cranial nerve: is there a relation to the headache phase of migraine? Lancet (1979) 1.14
Developmental cell death in dopaminergic neurons of the substantia nigra of mice. J Comp Neurol (2000) 1.12
Aromatic L-amino acid decarboxylase in rat corpus striatum: implications for action of L-dopa in parkinsonism. Neurology (1981) 1.11
Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity. Proc Natl Acad Sci U S A (1998) 1.11
Protective effect of insulin-like-growth-factor-1 against dopamine-induced neurotoxicity in human and rodent neuronal cultures: possible implications for Parkinson's disease. Neurosci Lett (2001) 1.10
The prognostic value of the CT scan in conservatively treated patients with intracerebral hematoma. Stroke (1984) 1.09
Skin biopsy for assessment of autonomic denervation in Parkinson's disease. J Neural Transm (Vienna) (2006) 1.09
Paroxysmal dystonia as the initial manifestation of multiple sclerosis. Arch Neurol (1984) 1.08
Increased survival and migration of engrafted mesenchymal bone marrow stem cells in 6-hydroxydopamine-lesioned rodents. Neurosci Lett (2005) 1.06
Nonaminergic striatal neurons convert exogenous L-dopa to dopamine in parkinsonism. Ann Neurol (1980) 1.05
Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease. Mov Disord (2001) 1.05
The European Multiple System Atrophy-Study Group (EMSA-SG). J Neural Transm (Vienna) (2005) 1.05
Integral therapeutic potential of bone marrow mesenchymal stem cells. Curr Drug Targets (2005) 1.05
Enhanced oxidative stress and altered antioxidants in brains of Bcl-2-deficient mice. J Neurochem (1998) 1.05
Direct localisation of beta-adrenoceptor sites in rat cerebellum by a new fluorescent analogue of propranolol. Nature (1976) 1.04
Induction of neuronal apoptosis by Semaphorin3A-derived peptide. Brain Res Mol Brain Res (2000) 1.03
Gastric emptying in Parkinson's disease: patients with and without response fluctuations. Neurology (1996) 1.02
Early-morning dystonia. A late side effect of long-term levodopa therapy in Parkinson's disease. Arch Neurol (1979) 1.02
Hemiballismus: detection of focal hemorrhage in subthalamic nucleus by CT scan. Ann Neurol (1978) 1.02
Regenerative effect of neural-induced human mesenchymal stromal cells in rat models of Parkinson's disease. Cytotherapy (2008) 1.01
Intravenous immunoglobulin treatment of experimental T cell-mediated autoimmune disease. Upregulation of T cell proliferation and downregulation of tumor necrosis factor alpha secretion. J Clin Invest (1994) 1.00
The site of dopamine formation in rat striatum after L-dopa administration. J Pharmacol Exp Ther (1981) 0.99
Prevention of dopamine-induced cell death by thiol antioxidants: possible implications for treatment of Parkinson's disease. Exp Neurol (1996) 0.99
Diagnosis of "non-organic" limb paresis by a novel objective motor assessment: the quantitative Hoover's test. J Neurol (1998) 0.98
Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson's disease. Brain Res (2000) 0.98
Circling behavior in rats with partial, unilateral nigro-striatal lesions: effect of amphetamine, apomorphine, and DOPA. Pharmacol Biochem Behav (1980) 0.97
Dopamine induces apoptosis-like cell death in cultured chick sympathetic neurons--a possible novel pathogenetic mechanism in Parkinson's disease. Neurosci Lett (1994) 0.97
Hemispheric brain damage in unilateral status epilepticus. Ann Neurol (1986) 0.97
Glutaredoxin protects cerebellar granule neurons from dopamine-induced apoptosis by activating NF-kappa B via Ref-1. J Biol Chem (2001) 0.97
Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa. Clin Neuropharmacol (2001) 0.96
Glutaredoxin protects cerebellar granule neurons from dopamine-induced apoptosis by dual activation of the ras-phosphoinositide 3-kinase and jun n-terminal kinase pathways. J Biol Chem (2001) 0.96
Primary progressive freezing gait. Mov Disord (1993) 0.96
Reversible central nervous system dysfunction in folate deficiency. J Neurol Sci (1975) 0.96
The synthesis of prostaglandins by bovine cerebral microvessels. Prostaglandins Med (1980) 0.95
Whole genome analysis in a consanguineous family with early onset Alzheimer's disease. Neurobiol Aging (2008) 0.95
Stroke in Jerusalem district 1960 through 1967: an epidemiological study. Stroke (1973) 0.95
Membranous lupus nephritis with antineutrophil cytoplasmic antibody-associated segmental necrotizing and crescentic glomerulonephritis. Am J Kidney Dis (1997) 0.94
Fatigue in multiple sclerosis compared with chronic fatigue syndrome: A quantitative assessment. Neurology (1996) 0.94
Episodic unresponsiveness to single doses of L-dopa in parkinsonian fluctuators. Neurology (1986) 0.94
Stimulation of nigrostriatal dopamine neurones by nicotine. Neuropharmacology (1982) 0.94
Chronic subdural hematoma simulating transient cerebral ischemic attacks. Case report. J Neurosurg (1975) 0.93
Impaired absorption of oral levodopa: a major cause for response fluctuations in Parkinson's disease. Isr J Med Sci (1996) 0.92
Regional cerebral blood flow in patients with Parkinson's disease. Arch Neurol (1979) 0.91
Progressive brain atrophy during normal aging in man: a quantitative computerized tomography study. Isr J Med Sci (1985) 0.91
Suppression of L-dopa-induced circling in rats with nigral lesions by blockade of central dopa-decarboxylase: implications for mechanism of action of L-dopa in parkinsonism. Neurology (1984) 0.90
Spinal dural arteriovenous fistulae--a diagnostic challenge. Isr Med Assoc J (2001) 0.90
Dopamine-induced programmed cell death in mouse thymocytes. Biochim Biophys Acta (1995) 0.89
Anterior horn of the lateral meniscus: another potential pitfall in MR imaging of the knee. Radiology (1997) 0.89
Levodopa in the treatment of Parkinson's disease: a consensus meeting. Mov Disord (1999) 0.89
Acute central nervous system complications after pulse steroid therapy in patients with systemic lupus erythematosus. J Rheumatol (1990) 0.88
Cortical blindness as a manifestation of basilar artery occlusion. Eur Neurol (1974) 0.88
Hypervitaminosis A in two hemodialysis patients. Am J Kidney Dis (1995) 0.88
The assessment of changes in brain volume using combined linear measurements. A CT-scan study. Neuroradiology (1984) 0.88
The effect of acute stroke on cardiac functions as observed in an intensive stroke care unit. Stroke (1975) 0.88
6-Hydroxydopamine increases ubiquitin-conjugates and protein degradation: implications for the pathogenesis of Parkinson's disease. Cell Mol Neurobiol (2001) 0.87
Abnormal skin wrinkling in the less affected side in hemiparkinsonism-a possible test for sympathetic dysfunction in Parkinson's disease. Biomed Pharmacother (2001) 0.87
Early-occurrence of manual motor blocks in Parkinson's disease: a quantitative assessment. Acta Neurol Scand (1999) 0.87
Partial lesions of the nigrostriatal pathway in the rat. Acceleration of transmitter synthesis and release of surviving dopaminergic neurones by drugs. Neuropharmacology (1985) 0.87
Activation of nuclear transcription factor kappa B (NF-kappaB) is essential for dopamine-induced apoptosis in PC12 cells. J Neurochem (2001) 0.87
Hypertension and diabetes as risk factors in stroke patients. Stroke (1974) 0.87
Machado-Joseph (Azorean) disease in a Yemenite Jewish family in Israel. Neurology (1994) 0.87
The regional cerebral blood flow in patients under chronic hemodialytic treatment. J Cereb Blood Flow Metab (1987) 0.86
Late-onset progressive radiculomyelopathy in patients with cervical athetoid-dystonic cerebral palsy. Eur Neurol (1987) 0.86